Developer docs
API playgroundTry for free, no card

Search company profiles

EthOss Regeneration

Full company profile

uuid000vfbx

Namestring
EthOss Regeneration
Legal namestring
Ethoss Regeneration Ltd
Websiteurl
ethoss.dental
Company typeenum
Private
Founded yearint
2013
Descriptiontext

EthOss Regeneration Ltd is a UK-based medical device company that develops and commercialises a 100% synthetic bone graft biomaterial for dental implant surgery. Founded in 2013 in West Yorkshire by dental surgeon Dr Peter Fairbairn and biomaterial specialist Dr Paul Harrison, the company's flagship product — EthOss Bone Graft Material — combines 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate in a syringe-applicator delivery format (0.25cc, 0.5cc, 1cc). The calcium sulphate component sets in situ to form a cell-occlusive barrier, eliminating the need for a separate collagen membrane, and the material is designed to be fully resorbed and replaced by host bone within 6–12 months. The company holds ISO 13485 and ISO 14001 certifications, and its technology has been used in over 100,000 surgical procedures worldwide.

The company operates an exclusively distributor-led go-to-market model, selling through a network of regional and country-specific exclusive distributors covering 65+ markets across Europe, the Middle East, Asia Pacific, Africa, and Latin America. It supplements its product with a substantial clinician-education ecosystem: 31 clinical publications, 66 case studies, 77 archived webinars, the EdgeX blended-learning platform, and a global 'EthOss Case Studies' Facebook community of over 11,000 clinicians, plus a patient-facing 'Find Your EthOss Clinic' interactive map that funnels patients to certified practitioners. EthOss reported net sales of approximately £5.4 million for the year ending July 2025 with a staff of ~16. In Q1 2026, Swedish Nasdaq-listed industrial conglomerate Lifco AB acquired a majority stake, consolidating EthOss into Lifco's Business Area Dental segment.

Short descriptiontext

EthOss Regeneration is a UK medical device company that develops a 100% synthetic 65% β-TCP / 35% calcium sulphate bone graft material for dental implant surgery, sold via exclusive distributors in 65+ markets to clinicians and oral surgeons globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSilsden, United Kingdom
HQ citystring
Silsden
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic bone grafts, dental implant materials, bone regeneration biomaterials, calcium phosphate grafts, oral surgery supplies
Industry1 code
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Dental Equipment and Supplies Manufacturing339114
  • Surgical Appliance and Supplies Manufacturing339113
SIC code3 codes
  • Dental Equipment & Supplies3843
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Dental Bone Graft Biomaterials
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Synthetic Bone Graft Material)
TypeOne Time License
Description

EthOss generates revenue through the sale of its synthetic bone graft material to dental clinicians and oral surgeons globally via its distributor network. The product is sold in unit sizes of 0.25cc, 0.5cc, and 1cc syringes. Revenue for the year ending July 2025 was approximately £5.4 million.

business-sale.com
2Practice/Specialist Programme
TypeAffiliate Referral
Description

EthOss enrols dental practices as certified specialists on its interactive patient-facing clinic map, which drives patient referrals to practitioners using EthOss, indirectly supporting product revenue through increased demand.

ethoss.dental
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Operations, Personnel, Supply Chain
Pricing details1 tier
1Pricing not publicly disclosed; quote-based distribution model.
ModelOtherBilling cadencePay-as-you-go
Notes

No pricing information is published on the EthOss website. Distributors and end customers must contact the company or local distributor for pricing. Product is available in 3 sizes: 0.25cc, 0.5cc, and 1cc.

ethoss.dental
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1EthOss Bone Graft
Description

The company's flagship synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate and 35% calcium sulphate.

ethoss.dental
+1 more record
Core offering1 text field

EthOss develops, manufactures, and sells a 100% synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate. The product is delivered in ready-to-use syringe applicators in three sizes (0.25cc, 0.5cc, and 1cc), mixed with standard sterile saline at the point of use. The calcium sulphate component sets in situ to form an integrated cell-occlusive barrier that eliminates the need for a separate collagen membrane, and the material is fully resorbed and replaced by the patient's own host bone within 6–12 months.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 50% resorbed and replaced by new host bone at 12 weeks; 85% at 33 weeks
+4 more records
Product overview1 text field

EthOss Regeneration offers a single flagship product - the EthOss Bone Graft Material - supported by a suite of clinical education and training resources. The core product is a 100% synthetic bone graft material designed for dental implant surgery, featuring an innovative combination of beta tricalcium phosphate and calcium sulfate that eliminates the need for separate collagen membranes. The company supplements its product offering with EdgeX (a blended learning experience), an extensive publications library of clinical research, virtual seminar archives, and a collection of case study books. The product is delivered in syringe applicators in three sizes (0.25cc, 0.5cc, 1cc) and is sold through a global network of exclusive distributors in over 65 markets worldwide.

Product and service1 record
1EthOss Bone Graft Material
CategoryDental bone graft biomaterial
Description

A 100% synthetic alloplastic bone graft biomaterial for dental implant and oral surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate in a syringe applicator. The calcium sulphate sets in situ to form a built-in cell-occlusive membrane, eliminating the need for a separate collagen membrane, and the material is fully resorbed and replaced by host bone within 6-12 months. Available in 0.25cc, 0.5cc, and 1cc sizes; sold to dental clinicians and oral surgeons globally via exclusive distributors in over 65 markets.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

EthOss operates through a network of exclusive distributors across over 65 markets globally. Key distributors include MegaGen Benelux, Southern Implants (Greece, France, UAE, South Africa, Australia), Swallow Dental Supplies (UK), Dental Shop Albania, Zantomed GmbH (Germany), and many others covering Europe, Africa, Asia, Middle East, Australasia, and South America. Distributors receive extensive training, sales and marketing support, and access to clinical speakers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1botiss biomaterials
TypeDirect peer
Description

German dental bone graft and regenerative materials company offering alloplast, xenograft, and allograft products plus membranes. Direct competitor to EthOss in the synthetic/alloplast dental regeneration segment across European and global markets.

2Dentsply Sirona
TypeBroad incumbent
Description

Largest dedicated dental equipment and materials manufacturer globally, with a regenerative and surgical solutions portfolio. Overlaps with EthOss in dental bone grafting and surgical consumables sold through dental distribution.

TypeBroad incumbent
Description

Largest dental distributor globally with a growing portfolio of own-brand and partner dental regenerative products. Comparable go-to-market through dental professionals and specialist practices.

TypeBroad incumbent
Description

Swiss global dental implant leader (Straumann, Neodent, Medentika) with an expanding regenerative portfolio. Competes with EthOss indirectly via integrated implant-plus-graft solutions and has the scale and KOL access that EthOss lacks.

TypeBroad incumbent
Description

Diversified medical device leader with a dental and CMF regenerative materials portfolio including allograft and synthetic bone graft substitutes. Adjacent competitor with deep regulatory and clinical infrastructure.

TypeBroad incumbent
Description

French global leader in dental pharmaceuticals and biomaterials, with bone graft substitute and regenerative products sold to dentists and oral surgeons. Comparable customer base and dental specialty channel.

TypeBroad incumbent
Description

Global orthopedic and dental player with a dental regenerative materials business (including RegenerOss allograft and synthetic bone graft substitutes). Comparable product category with significantly broader resources.

TypeEmerging player
Description

US-based dental surgical and regenerative products specialist selling bone graft materials, membranes, and surgical kits to implantologists. Comparable niche focus on the same clinician base but with a primarily xenograft/allograft portfolio.

TypeBroad incumbent
Description

Dental-focused parent of Kerr, Nobel Biocare, and Ormco. Competes in dental implant workflows including bone grafting and regenerative materials distributed through dental channels globally.

TypeDirect peer
Description

Swiss manufacturer of Bio-Oss (bovine xenograft) and Bio-Gide collagen membrane, the gold-standard dental bone graft and membrane combination against which EthOss directly competes. Highly comparable product category, customer base (implantologists and oral surgeons), and clinical use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EthOss Regeneration

Dental Bone Graft Biomaterialsethoss.dental

EthOss Regeneration is a UK medical device company that develops a 100% synthetic 65% β-TCP / 35% calcium sulphate bone graft material for dental implant surgery, sold via exclusive distributors in 65+ markets to clinicians and oral surgeons globally.

What EthOss Regeneration does

EthOss Regeneration Ltd is a UK-based medical device company that develops and commercialises a 100% synthetic bone graft biomaterial for dental implant surgery. Founded in 2013 in West Yorkshire by dental surgeon Dr Peter Fairbairn and biomaterial specialist Dr Paul Harrison, the company's flagship product — EthOss Bone Graft Material — combines 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate in a syringe-applicator delivery format (0.25cc, 0.5cc, 1cc). The calcium sulphate component sets in situ to form a cell-occlusive barrier, eliminating the need for a separate collagen membrane, and the material is designed to be fully resorbed and replaced by host bone within 6–12 months. The company holds ISO 13485 and ISO 14001 certifications, and its technology has been used in over 100,000 surgical procedures worldwide.

The company operates an exclusively distributor-led go-to-market model, selling through a network of regional and country-specific exclusive distributors covering 65+ markets across Europe, the Middle East, Asia Pacific, Africa, and Latin America. It supplements its product with a substantial clinician-education ecosystem: 31 clinical publications, 66 case studies, 77 archived webinars, the EdgeX blended-learning platform, and a global 'EthOss Case Studies' Facebook community of over 11,000 clinicians, plus a patient-facing 'Find Your EthOss Clinic' interactive map that funnels patients to certified practitioners. EthOss reported net sales of approximately £5.4 million for the year ending July 2025 with a staff of ~16. In Q1 2026, Swedish Nasdaq-listed industrial conglomerate Lifco AB acquired a majority stake, consolidating EthOss into Lifco's Business Area Dental segment.

EthOss Regeneration firmographics

Firmographics
Name
EthOss Regeneration
Legal name
Ethoss Regeneration Ltd
Website
https://ethoss.dental
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
EthOss Regeneration is a UK medical device company that develops a 100% synthetic 65% β-TCP / 35% calcium sulphate bone graft material for dental implant surgery, sold via exclusive distributors in 65+ markets to clinicians and oral surgeons globally.
Ownership category
akta.pro rank

EthOss Regeneration industry classification

Industry
Product category
Dental Bone Graft Biomaterials
NAICS
Dental Equipment and Supplies Manufacturing (339114), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Dental Equipment & Supplies (3843), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Synthetic bone grafts
  • Dental implant materials
  • Bone regeneration biomaterials
  • Calcium phosphate grafts
  • Oral surgery supplies

Where EthOss Regeneration is headquartered

Location

Headquarters

HQ city
Silsden
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

EthOss Regeneration business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Operations, Personnel, Supply Chain

Revenue model

  1. Product Sales (Synthetic Bone Graft Material): EthOss generates revenue through the sale of its synthetic bone graft material to dental clinicians and oral surgeons globally via its distributor network. The product is sold in unit sizes of 0.25cc, 0.5cc, and 1cc syringes. Revenue for the year ending July 2025 was approximately £5.4 million.
  2. Practice/Specialist Programme: EthOss enrols dental practices as certified specialists on its interactive patient-facing clinic map, which drives patient referrals to practitioners using EthOss, indirectly supporting product revenue through increased demand.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPricing not publicly disclosed; quote-based distribution model.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

EthOss Regeneration product offering

Product offering

Core offering

EthOss develops, manufactures, and sells a 100% synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate. The product is delivered in ready-to-use syringe applicators in three sizes (0.25cc, 0.5cc, and 1cc), mixed with standard sterile saline at the point of use. The calcium sulphate component sets in situ to form an integrated cell-occlusive barrier that eliminates the need for a separate collagen membrane, and the material is fully resorbed and replaced by the patient's own host bone within 6–12 months.

Product overview

EthOss Regeneration offers a single flagship product - the EthOss Bone Graft Material - supported by a suite of clinical education and training resources. The core product is a 100% synthetic bone graft material designed for dental implant surgery, featuring an innovative combination of beta tricalcium phosphate and calcium sulfate that eliminates the need for separate collagen membranes. The company supplements its product offering with EdgeX (a blended learning experience), an extensive publications library of clinical research, virtual seminar archives, and a collection of case study books. The product is delivered in syringe applicators in three sizes (0.25cc, 0.5cc, 1cc) and is sold through a global network of exclusive distributors in over 65 markets worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • EthOss Bone Graft: The company's flagship synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate and 35% calcium sulphate.
  • EdgeX

Products and services

  • EthOss Bone Graft Material A 100% synthetic alloplastic bone graft biomaterial for dental implant and oral surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate in a syringe applicator. The calcium sulphate sets in situ to form a built-in cell-occlusive membrane, eliminating the need for a separate collagen membrane, and the material is fully resorbed and replaced by host bone within 6-12 months. Available in 0.25cc, 0.5cc, and 1cc sizes; sold to dental clinicians and oral surgeons globally via exclusive distributors in over 65 markets.

Quantifiable outcome

  • 50% resorbed and replaced by new host bone at 12 weeks; 85% at 33 weeks
  • +4 more outcomes

Companies that use EthOss Regeneration

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles2 records

EthOss Regeneration technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

EthOss Regeneration partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Global Distributor NetworkcoreChannel Partner/ Reseller/ DistributorEthOss operates through a network of exclusive distributors across over 65 markets globally. Key distributors include MegaGen Benelux, Southern Implants (Greece, France, UAE, South Africa, Australia), Swallow Dental Supplies (UK), Dental Shop Albania, Zantomed GmbH (Germany), and many others covering Europe, Africa, Asia, Middle East, Australasia, and South America. Distributors receive extensive training, sales and marketing support, and access to clinical speakers.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

EthOss Regeneration competitors and assessment

Company assessment

Direct peers

  • botiss biomaterials: German dental bone graft and regenerative materials company offering alloplast, xenograft, and allograft products plus membranes. Direct competitor to EthOss in the synthetic/alloplast dental regeneration segment across European and global markets.
  • Geistlich Pharma: Swiss manufacturer of Bio-Oss (bovine xenograft) and Bio-Gide collagen membrane, the gold-standard dental bone graft and membrane combination against which EthOss directly competes. Highly comparable product category, customer base (implantologists and oral surgeons), and clinical use cases.

Broad incumbents

  • Dentsply Sirona: Largest dedicated dental equipment and materials manufacturer globally, with a regenerative and surgical solutions portfolio. Overlaps with EthOss in dental bone grafting and surgical consumables sold through dental distribution.
  • Henry Schein: Largest dental distributor globally with a growing portfolio of own-brand and partner dental regenerative products. Comparable go-to-market through dental professionals and specialist practices.
  • Straumann Group: Swiss global dental implant leader (Straumann, Neodent, Medentika) with an expanding regenerative portfolio. Competes with EthOss indirectly via integrated implant-plus-graft solutions and has the scale and KOL access that EthOss lacks.
  • Medtronic (Dental and Craniomaxillofacial): Diversified medical device leader with a dental and CMF regenerative materials portfolio including allograft and synthetic bone graft substitutes. Adjacent competitor with deep regulatory and clinical infrastructure.
  • Septodont: French global leader in dental pharmaceuticals and biomaterials, with bone graft substitute and regenerative products sold to dentists and oral surgeons. Comparable customer base and dental specialty channel.
  • Zimmer Biomet: Global orthopedic and dental player with a dental regenerative materials business (including RegenerOss allograft and synthetic bone graft substitutes). Comparable product category with significantly broader resources.
  • Envista Holdings (Kerr Dental): Dental-focused parent of Kerr, Nobel Biocare, and Ormco. Competes in dental implant workflows including bone grafting and regenerative materials distributed through dental channels globally.

Emerging players

  • Salvin Dental Specialties: US-based dental surgical and regenerative products specialist selling bone graft materials, membranes, and surgical kits to implantologists. Comparable niche focus on the same clinician base but with a primarily xenograft/allograft portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EthOss Regeneration social profiles

Digital presence

EthOss Regeneration compliance and trust

Trust signal

Compliance3 records

EthOss Regeneration financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EthOss Regeneration leadership team

Management profile

Number of profiles

Profiles1 record

EthOss Regeneration funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EthOss Regeneration M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EthOss Regeneration

What does EthOss Regeneration do?

EthOss develops, manufactures, and sells a 100% synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate. The product is delivered in ready-to-use syringe applicators in three sizes (0.25cc, 0.5cc, and 1cc), mixed with standard sterile saline at the point of use. The calcium sulphate component sets in situ to form an integrated cell-occlusive barrier that eliminates the need for a separate collagen membrane, and the material is fully resorbed and replaced by the patient's own host bone within 6–12 months.

Is EthOss Regeneration a public or private company?

EthOss Regeneration is a private company. It is classified as corporate owned and is currently operating.

When was EthOss Regeneration founded?

EthOss Regeneration was founded in 2013. It employs 11 to 50 people.

Where is EthOss Regeneration based?

EthOss Regeneration is headquartered in Silsden, United Kingdom, in the Europe region.

How does EthOss Regeneration make money?

Two revenue lines are on record. Product Sales (Synthetic Bone Graft Material) is the primary driver. The others are practice/Specialist Programme.

Who are EthOss Regeneration's main competitors?

Direct peers on record are botiss biomaterials and Geistlich Pharma. Broad incumbents are Dentsply Sirona, Henry Schein, Straumann Group, Medtronic (Dental and Craniomaxillofacial), Septodont, Zimmer Biomet and Envista Holdings (Kerr Dental). Salvin Dental Specialties is listed as an emerging player.

Does EthOss Regeneration have an API?

No public API is recorded for EthOss Regeneration.

What industry is EthOss Regeneration in?

EthOss Regeneration's product category is Dental Bone Graft Biomaterials. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339114 and its SIC code is 3843.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals